Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment.

Results showed that patients with ACS following the experimental strategy had a lower risk of the primary endpoint (2.95% versus 5.26%; HR 0.55; 95% CI [0.35–0.89]; p=0.014; p for interaction with stable CAD patients = 0.032), driven by a lower risk of all-cause mortality (2.19% versus 4.28%; HR 0.51; 95% CI [0.30–0.87]; p=0.013; p for interaction with stable CAD patients = 0.021), as well as a marginally significant reduced risk of bleeding (HR 0.58; 95% CI [0.33–1.01]; p=0.053; p for interaction with stable CAD patients = 0.334) compared with patients receiving the reference regimen.[ 19 ] In the same direction, the TWILIGHT-COMPLEX study, a post-hoc analysis of the TWILIGHT trial, evaluated the effects of ticagrelor monotherapy compared to DAPT with aspirin plus ticagrelor in 2,342 event-free patients who had completed 3 months of DAPT.

also in 26,082 other papers